Association of paraoxonase activity and atherosclerosis in patients with chronic hepatitis B

African Health Sciences

Volumn 12, Issue 2, 2012, Pages 114-118

  Karsen, H ^a   Binici, I ^b   Sunnetcioglu, M ^b   Baran, A I ^b   Ceylan, M R ^b   Selek, S ^a   Celik, H ^a  

^a HARRAN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

Atherosclerosis; Chronic hepatitis B; Oxidative status; Paraoxonase activity

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN; THIOL GROUP; TRIACYLGLYCEROL;

AGE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; FEMALE; GENDER; HEPATITIS B; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC PARAMETERS; OXIDATIVE STATUS; OXIDATIVE STRESS; TOTAL ANTIOXIDANT CAPACITY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BODY MASS INDEX; CARBOXYLIC ESTER HYDROLASES; CASE-CONTROL STUDIES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIPID PEROXIDES; LIPIDS; MALE; MIDDLE AGED; OXIDANTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; RISK FACTORS; SULFHYDRYL COMPOUNDS;

EID: 84864374667     PISSN: 16806905     EISSN: None     Source Type: Journal    
DOI: 10.4314/ahs.v12i2.6     Document Type: Article

References (20)

1. Irshad M, Chaudhuri PS, Joshi YK. Superoxide dismutase and total anti-oxidant levels in various forms of liver diseases. Hepatol Res 2002; 23:178-184.
2. Demirdag K, Yilmaz S, Ozdarendeli A, Ozden M, Kalkan A, Kilic SS. Levels of plasma malondialdehyde and erythrocyte antioxidant enzyme activities in patients with chronic hepatitis B. Hepatogastroenterology 2003; 50:766-770.
3. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 2006; 187:74.
4. Canales A, Sanchez-Muniz FJ. Paraoxanase, something more than an enzyme? Med Clin (Barc) 2003; 121:537-548.
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
6. Seres I, Paragh G, Deschene E, Fulop T Jr, Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp gerontol 2004; 39:59-66.
7. Eckerson HW, Wyte MC, la Du BN. The human serum paroxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35:1126-1138.
8. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82:70-77.
9. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004; 37:112-119.
10. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004; 37:277-285.
11. Pasqualini L, Cortese C, Marchesi S, Siepi D, Pirro M, Vaudo G, et al. Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 2005; 183:349-354.
12. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005; 38:1103-1111.
13. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003; 54:371-392.
14. Draganov DI, la Du BN. Pharmacogenetics of paraoxonase: a brief review. Naunyn's Schmiedeberg's Arch Pharmacol 2004; 369:79-88.
15. Malin R, Knuuti J, Janatuinen T, Laaksonen R, Vesalainen R, Nuutila P, et al. Paraoxonase gene polymorphisms and coronary reactivity in young healthy men. J Mol Med 2001; 79:449-458.
16. Alkhouri N, Tamimi TA, Yerian L, Lopez R, Zein NN, Feldstein AE. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci. 2010; 55(9):2644-2650.
17. Wang CH, Chen CJ, Lee MH, Yang HI, Hsiao CK. Chronic hepatitis B infection and risk of atherosclerosis-related mortality: A 17-year followup study based on 22,472 residents in Taiwan. Atherosclerosis. 2010; 211(2):624-629.
18. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, et al. Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21:1451-1457.
19. Rozenberg O, Aviram M. S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity. Biochem Biophys Res Commun 2006; 351:492-498.
20. Rontu R, Karhunen PJ, Ilveskoski E, Mikkelsson J, Kajander O, Perola M, et al. Smoking-dependent association between paraoxonase 1 M/L55 genotype and coronary atherosclerosis in males: an autopsy study. Atherosclerosis 2003; 171:31-37.